Paper33737643
A dose-escalating toxicology study of the candidate biologic ELP-VEGF.
Waller JP and 4 others. Sci Rep, 2021. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. A dose-escalating toxicology study of the candidate biologic ELP-VEGF. Papers, record 33737643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33737643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics26
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biological Products | Major topic |
| Breast Neoplasms | Major topic |
| Elastin | Major topic |
| Neovascularization, Pathologic | Major topic |
| Recombinant Fusion Proteins | Major topic |
| Renal Insufficiency, Chronic | Major topic |
| Vascular Endothelial Growth Factor A | Major topic |
| Animals | |
| Blood Pressure | |
| Body Weight | |
| Capillary Permeability | |
| Disease Models, Animal | |
| Female | |
| Gene Expression | |
| Glomerular Filtration Rate | |
| Heterografts | |
| Humans | |
| Hypotension | |
| Mice | |
| Molecular Mimicry | |
| Neovascularization, Physiologic | |
| Rats | |
| Rats, Sprague-Dawley | |
| Swine | |
| Toxicity Tests, Chronic | |
| X-Ray Microtomography |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 HL121527 | NHLBI NIH HHS | United States | R01HL121527 | PubMed and NIH | NIH RePORTER |
| P20 GM104357 | NIGMS NIH HHS | United States | P20GM104357 | PubMed and NIH | NIH RePORTER |
| R01 HL095638 | NHLBI NIH HHS | United States | R01HL095638 | PubMed and NIH | NIH RePORTER |
| F31 HL151180 | NHLBI NIH HHS | United States | F31HL151180 | PubMed and NIH | NIH RePORTER |
| R41 DK109737 | NIDDK NIH HHS | United States | R41DK109737 | PubMed and NIH | NIH RePORTER |
| P01 HL051971 | NHLBI NIH HHS | United States | P01HL051971 | PubMed and NIH | NIH RePORTER |
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29477157 | US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States. | Am J Kidney Dis | 2018 | https://conductscience.org/library/papers/29477157 | PubMed |
| 2 | 25704344 | Epidemiology of hypertension in CKD. | Adv Chronic Kidney Dis | 2015 | https://conductscience.org/library/papers/25704344 | PubMed |
| 3 | 19244479 | Chronic hypoxia attenuates VEGF signaling and angiogenic responses by downregulation of KDR in human endothelial cells. | Am J Physiol Cell Physiol | 2009 | https://conductscience.org/library/papers/19244479 | PubMed |
| 4 | 19934087 | Role of renal microcirculation in experimental renovascular disease. | Nephrol Dial Transplant | 2010 | https://conductscience.org/library/papers/19934087 | PubMed |
| 5 | 20587789 | Renal microvascular disease determines the responses to revascularization in experimental renovascular disease. | Circ Cardiovasc Interv | 2010 | https://conductscience.org/library/papers/20587789 | PubMed |
| 6 | 31542966 | Targeted VEGF (Vascular Endothelial Growth Factor) Therapy Induces Long-Term Renal Recovery in Chronic Kidney Disease via Macrophage Polarization. | Hypertension | 2019 | https://conductscience.org/library/papers/31542966 | PubMed |
| 7 | 22357917 | Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: a novel potential therapeutic approach. | Am J Physiol Renal Physiol | 2012 | https://conductscience.org/library/papers/22357917 | PubMed |
| 8 | 25653833 | Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. | Vasc Cell | 2015 | https://conductscience.org/library/papers/25653833 | PubMed |
| 9 | 12152001 | A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. | Clin Pharmacol Ther | 2002 | https://conductscience.org/library/papers/12152001 | PubMed |
| 10 | 1464614 | Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. | J Biol Chem | 1992 | https://conductscience.org/library/papers/1464614 | PubMed |
| 11 | 963023 | Synthetic, cross-linked polypentapeptide fo tropoelastin: an anisotropic, fibrillar elastomer. | Biochemistry | 1976 | https://conductscience.org/library/papers/963023 | PubMed |
| 12 | 26578439 | Elastin-like polypeptides: Therapeutic applications for an emerging class of nanomedicines. | J Control Release | 2016 | https://conductscience.org/library/papers/26578439 | PubMed |
| 13 | 31786977 | Biopolymer-Delivered, Maternally Sequestered NF-κB (Nuclear Factor-κB) Inhibitory Peptide for Treatment of Preeclampsia. | Hypertension | 2020 | https://conductscience.org/library/papers/31786977 | PubMed |
| 14 | 25823650 | Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides. | Pharm Res | 2015 | https://conductscience.org/library/papers/25823650 | PubMed |
| 15 | 27784692 | A kidney-selective biopolymer for targeted drug delivery. | Am J Physiol Renal Physiol | 2017 | https://conductscience.org/library/papers/27784692 | PubMed |
| 16 | 26541349 | Renal Therapeutic Angiogenesis Using a Bioengineered Polymer-Stabilized Vascular Endothelial Growth Factor Construct. | J Am Soc Nephrol | 2016 | https://conductscience.org/library/papers/26541349 | PubMed |
| 17 | 29273331 | Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease. | Kidney Int | 2018 | https://conductscience.org/library/papers/29273331 | PubMed |
| 18 | 5043412 | Tumor dormancy in vivo by prevention of neovascularization. | J Exp Med | 1972 | https://conductscience.org/library/papers/5043412 | PubMed |
| 19 | 1940805 | Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. | J Exp Med | 1991 | https://conductscience.org/library/papers/1940805 | PubMed |
| 20 | 1309029 | Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. | Ann N Y Acad Sci | 1992 | https://conductscience.org/library/papers/1309029 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42776284 | Angiogenesis-promoting properties of phosphorylcholine mimetic nanoparticles. | Angiogenesis | 2026 | https://conductscience.org/library/papers/42776284 | PubMed |
| 42514909 | Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42514909 | PubMed |
| 42165956 | Angiogenic Doping: Plausible Yet Difficult to Detect. | Sports Med | 2026 | https://conductscience.org/library/papers/42165956 | PubMed |
| 42094280 | Rational design and preclinical evaluation of elastin-like polypeptide micelle nanoparticles for drug delivery. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/42094280 | PubMed |
| 41837883 | Growth factor applications and clinical translation: advances and challenges. | Ann Med | 2026 | https://conductscience.org/library/papers/41837883 | PubMed |
| 41528341 | Optimizing delivery of an anti-cytomegalovirus inhibitory peptide using a cell-penetrating peptide. | J Gen Virol | 2026 | https://conductscience.org/library/papers/41528341 | PubMed |
| 40339045 | Value of Bioinformatics Models for Predicting Translational Control of Angiogenesis. | Circ Res | 2025 | https://conductscience.org/library/papers/40339045 | PubMed |
| 35652363 | Novel Drug Delivery Technologies and Targets for Renal Disease. | Hypertension | 2022 | https://conductscience.org/library/papers/35652363 | PubMed |
| 35215284 | Gelatin Methacrylate Hydrogel for Tissue Engineering Applications-A Review on Material Modifications. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/35215284 | PubMed |
| 34486397 | Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform. | Physiology (Bethesda) | 2021 | https://conductscience.org/library/papers/34486397 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| NR5A1 | 2516 | PubTator's text mining | https://conductscience.org/library/genes/2516 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33737643
GET https://conductscience.org/api/papers/v1/33737643/references?page=2